NY-INNOVATIVE-HEALTH
Andrew Sealfon, Chairman and Founder of Innovative Health Sciences LLC (“IHS”), today pledged 1,000 of his company’s unique portable non-electric IV pumps to victims of the Ukraine conflict.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005921/en/
The Insignis™ Syringe Infusion System includes a fully mechanical, non-electric infusion pump system and dedicated flow control devices for both intravenous and subcutaneous applications. The portable system operates independent of battery or electricity, allowing it to be stockpiled, transported, and stored for emergency situations in locations where resources may be scarce or absent. The Insignis™ system has undergone extensive testing and received ISO 13485 quality management system and CE mark certification in May 2021. The CE (Conformité Européene) mark enables IHS to sell the system throughout the European Union.
Unlike other infusers, the Insignis™ system enables the rate to be titrated and adjusted easily and quickly without drip chambers or inaccurate rate controllers. It consists of:
- Mechanical 13.5psi Syringe Driver
- Intravenous Controller
- OneSett™ Subcutaneous Administration Set
This system addresses 80-90% of the needs of infusion therapy, providing simplicity, safety, versatility, and usability. In emergency situations, it may be used for:
- Hypodermoclysis (subcutaneous rehydration when intravenous access is not feasible)
- Antibiotics or antivirals
- Fluid volume assist medications
The atrocities currently taking place in Ukraine have destroyed hospitals, wards, and care centers, crippling medical efforts. Sealfon and IHS are pledging 1,000 infusion pumps to help patients receive the care they most desperately need, as well as any education needed for optimal use of the system for Ukrainian soldiers and civilians.
The 1,000 Insignis™ pumps will be available for delivery over the next 60 days, and will be provided to third party agencies and bodies serving the victims of the conflict.
Sealfon and IHS are also coordinating private donations and setting up a GoFundMe page to allow for others to contribute additional Insignis™ pumps and ancillary supplies to victims of the Ukraine conflict. For more information, contact info@innohealthsci.com or visit https://gofund.me/508a32c3 .
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005921/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom